2021
Kynurenine metabolism and metabolic syndrome in patients with schizophrenia
Zhang P, Huang J, Gou M, Zhou Y, Tong J, Fan F, Cui Y, Luo X, Tan S, Wang Z, Yang F, Tian B, Li CR, Hong LE, Tan Y. Kynurenine metabolism and metabolic syndrome in patients with schizophrenia. Journal Of Psychiatric Research 2021, 139: 54-61. PMID: 34034146, DOI: 10.1016/j.jpsychires.2021.05.004.Peer-Reviewed Original ResearchConceptsMetabolic syndromeKP metabolitesMS scorePathogenesis of MSKynurenine pathway metabolismRegression analysisKynurenine metabolismPatient groupHealthy controlsMultiple linear regression analysisSchizophrenia patientsLinear regression analysisPathway metabolismPatientsContributory roleSchizophreniaHigh nicotinamide adenine dinucleotideNicotinamide adenine dinucleotideMS factorsPotential rolePartial correlation analysisScoresMultiple regression analysisSyndromePathogenesis
2019
Effects of Antipsychotic Treatment on S100B and Oxidative Stress in Patients with Schizophrenia
Wang X, Bian Y, Liu L, Wu Y, Yang F, Li X, Han X, Tian L, Luo X, Chen S, Wang Z, Tan Y, Li Y. Effects of Antipsychotic Treatment on S100B and Oxidative Stress in Patients with Schizophrenia. Global Clinical And Translational Research 2019, 120-127. DOI: 10.36316/gcatr.01.0018.Peer-Reviewed Original ResearchDrug-naive patientsLevels of S100BFirst-episode drug-naive patientsAntipsychotic treatmentTotal oxidative statusAcute-phase schizophreniaLevels of malondialdehydeAcute phasePatient groupOxidative stressAcute phase patientsDSM-IV diagnostic criteriaAntipsychotic treatment effectsPANSS negative scoresNegative Syndrome ScaleRandom-effects modelSerum S100BPhase patientsSerum levelsDiagnostic criteriaPatientsSyndrome ScaleS100BRisperidoneOxidative statusElevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia
Tong J, Huang J, Luo X, Chen S, Cui Y, An H, Xiu M, Tan S, Wang Z, Yuan Y, Zhang J, Yang F, Li CR, Hong L, Tan Y. Elevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia. Brain Behavior And Immunity 2019, 81: 213-219. PMID: 31201848, PMCID: PMC6754783, DOI: 10.1016/j.bbi.2019.06.017.Peer-Reviewed Original ResearchConceptsN-methyl-D-aspartate (NMDA) glutamate receptorsFirst-episode patientsNMDAR antibodiesAntibody levelsHealthy controlsSerum anti-NMDAR antibodyTotal scoreAnti-NMDAR antibodiesNMDAR antibody levelsNMDAR-antibody encephalitisElevated levelsReceptor antibody levelsSerum antibody levelsTreatment of schizophreniaPathogenesis of schizophreniaNegative Syndrome ScaleSymptoms of psychosisEnzyme-linked immunosorbentEtiology of schizophreniaMCCB total scoreAntibody encephalitisPatient groupNMDAR dysfunctionSchizophrenia (MATRICS) Consensus Cognitive BatteryGlutamate receptors
2014
Smoking and BDNF Val66Met polymorphism in male schizophrenia: A case-control study
Zhang XY, Chen DC, Tan YL, Luo X, Zuo L, Lv MH, Shah NN, Zunta-Soares GB, Soares JC. Smoking and BDNF Val66Met polymorphism in male schizophrenia: A case-control study. Journal Of Psychiatric Research 2014, 60: 49-55. PMID: 25455509, DOI: 10.1016/j.jpsychires.2014.09.023.Peer-Reviewed Original ResearchConceptsVal/Val genotypeBDNF Val66Met polymorphismHealthy controlsNicotine dependenceVal66Met polymorphismVal genotypeSchizophrenia patientsChronic male schizophrenia patientsMet alleleBDNF Val66Met gene polymorphismBDNF Val66Met genotypePANSS negative symptomsHigher FTND scoresCase-control studyMale schizophrenia patientsNegative Syndrome ScaleChinese Han populationCase-control designVal66Met genotypeMore hospitalizationsPatient groupSmoking indexMale schizophreniaFagerstrom TestHigh HSI scores
2012
Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls
Zhang XY, Chen DC, Xiu MH, Haile CN, Luo X, Xu K, Zhang HP, Zuo L, Zhang Z, Zhang X, Kosten TA, Kosten TR. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Human Genetics 2012, 131: 1187-1195. PMID: 22362486, PMCID: PMC3671849, DOI: 10.1007/s00439-012-1150-x.Peer-Reviewed Original ResearchConceptsBDNF Val66Met polymorphismBDNF levelsRBANS total scoreHealthy controlsSchizophrenic patientsVal66Met polymorphismHippocampal-dependent cognitive functionsCognitive deficitsBrain-derived neurotrophic factor (BDNF) geneTotal scoreBDNF serum levelsBDNF Val66Met gene polymorphismPeripheral BDNF levelsSerum BDNF levelsMet variantNeurotrophic factor geneNegative Syndrome ScaleSerum BDNFSerum levelsPatient groupNormal controlsSchizophrenic inpatientsGene polymorphismsSyndrome ScaleCognitive impairment